<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56904">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752933</url>
  </required_header>
  <id_info>
    <org_study_id>SGI-110-03</org_study_id>
    <nct_id>NCT01752933</nct_id>
  </id_info>
  <brief_title>SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced
      hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a
      Simon's 2-stage design.  A set minimum number of patients must demonstrate disease control
      at 16 weeks to proceed to Stage 2. At Stage 2, a set number of patients must have disease
      control at 16 weeks to declare that SGI-110 is of interest in the treatment of advanced HCC
      after failure of prior sorafenib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assess the disease control rate (DCR) at 16 weeks for patients treated with SGI-110 after failure of sorafenib</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of patients achieving a best overall response of complete response or partial response and stable disease at 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability of SGI-110</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with serious adverse events and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine alpha fetoprotein response as a result of SGI-110 administration</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in alpha fetoprotein levels from pre-treatment levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response as measured in weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival measured in weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival measured in weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>SGI-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGI-110 administered subcutaneously daily on Days 1 - 5 every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110</intervention_name>
    <description>SGI-110 will be administered by subcutaneously on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity</description>
    <arm_group_label>SGI-110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Histological or cytological confirmed hepatocellular carcinoma with advanced stage
             disease

          3. Received prior sorafenib treatment, and showed evidence of disease progression, which
             is defined as Investigator verified radiologic progression, or intolerance of prior
             systemic therapy, which is defined as having had clinically significant adverse
             events that persisted despite one or more dose reductions or interruptions

          4. ECOG performance status of 0-1

          5. Acceptable organ function

          6. Signed an approved informed consent

        Exclusion Criteria:

          1. Known hypersensitivity to SGI-110

          2. Adequate washout of prior radiation, chemotherapy or other locoregional therapy

          3. Abnormal left ventricular ejection fraction

          4. Uncontrolled ischemic heart disease or a history of congestive cardiac failure

          5. Known brain metastases

          6. Clinically evident ascites

          7. Child-Pugh C cirrhosis or Child-Pugh B cirrhosis with more than 7 points

          8. Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, non-metastatic prostate cancer with normal PSA or
             other cancer from which the subject has been disease free for at least three years

          9. Known history of human immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medpace Recruitment Center</last_name>
    <phone>1-866-872-2349</phone>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Rose</last_name>
      <phone>626-359-8111</phone>
      <phone_ext>68245</phone_ext>
      <email>crose@coh.org</email>
    </contact>
    <investigator>
      <last_name>Marwan Fakih, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Agafitei</last_name>
      <phone>323-865-0467</phone>
      <email>Raluca.agafitei@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Romo</last_name>
      <phone>916-734-1455</phone>
      <email>christina.romo@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Semrad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Daniels</last_name>
      <phone>813-745-3960</phone>
      <email>david.daniels@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Richard Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University: Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Alonso</last_name>
      <phone>312-695-4168</phone>
      <email>erin.alonso@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Mulcahy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vivek Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Vulaj</last_name>
      <phone>212-342-0248</phone>
      <email>vv2218@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Abby Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanaa Tahiri</last_name>
      <phone>614-293-5894</phone>
      <email>sanaa.tahiri@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Marlow</last_name>
      <phone>215-214-1451</phone>
      <email>Becky.marlow@fccc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Dickens</last_name>
      <phone>215-214-3916</phone>
      <email>alexis.dickens@fccc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Crystal Denlinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andie Adelman</last_name>
      <phone>843-792-1507</phone>
      <email>adelman@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Melanie Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jones Clinic, PC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Lynch</last_name>
      <phone>901-685-5969</phone>
      <phone_ext>322</phone_ext>
      <email>llynch@jonescancerclinic.com</email>
    </contact>
    <investigator>
      <last_name>Michael C Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyson Dudley</last_name>
      <phone>214-648-7031</phone>
      <email>tyson.dudley@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Muhammad Beg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Gold, MD</last_name>
      <phone>206-386-2242</phone>
    </contact>
    <investigator>
      <last_name>Philip Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Crawford</last_name>
      <phone>608-265-4347</phone>
      <email>recrawford@uwcarbone.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>William Schelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia and Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alan Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Lister</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70305</phone_ext>
      <email>dilister@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Rakesh Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook HealthScience Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Lam</last_name>
      <phone>416-480-5000</phone>
      <phone_ext>7868</phone_ext>
      <email>adam.lam@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Yoo-Joung Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital St-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Girard</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>35281</phone_ext>
      <email>stephanie.girard.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Helene Castel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1N 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Andre Rodrigue</last_name>
      <phone>819-346-1110</phone>
      <email>marodrigue.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Annie Beaudoin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Liverpool Clatterbridge Cancer Center</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Palmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tim Meyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rohini Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 4AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bristi Basu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
